Wuhan YZY Biopharma Co., Ltd. (YZY Biopharma) filed its Monthly Return for the period ended 31 July 2026, confirming that the company’s share structure remained stable during the month.

Authorised and Issued Share Capital • Authorised/registered share capital stood at RMB 193.85 million, split between 179.48 million H-shares and 14.37 million domestic shares, each with a par value of RMB 1. • Issued share capital was unchanged: 179.48 million H-shares are listed in Hong Kong, while 14.37 million domestic shares remain unlisted. • No treasury shares were held or transferred, and no new shares were issued or cancelled in July.

Public Float • YZY Biopharma confirmed compliance with the Main Board’s 25 percent minimum public-float requirement as at 31 July 2026.

Share Option Activity • Under the 2024 H Share Option Plan (adopted 27 June 2024), 1.25 million options were outstanding at both the beginning and end of the month. • Potential dilution from currently outstanding options amounts to 312,500 H-shares. The plan still allows up to 18.13 million additional H-shares to be issued upon future grants and exercises.

Other Corporate Actions • The company reported no warrants, convertible securities, Hong Kong Depositary Receipts, or other share-linked arrangements in July.

The filing was signed by Joint Company Secretary Zheng Jianhua on 5 August 2026.